Human RCTPubMed ID: 38681423·2024

Retatrutide Improves Cardiometabolic Risk Markers Independent of Weight Loss

Lowe MR, Arslanian SA, Cefalu WT, et al.

Cardiovascular Diabetology, 2024 · n = 278

Key finding

Retatrutide reduced systolic BP by 8.2 ± 1.4 mmHg and LDL-C by 12% independent of weight loss magnitude, suggesting direct metabolic benefits.

Summary

Analysis of biomarkers in retatrutide trials showing effects on systolic/diastolic BP, lipid profile, and inflammatory markers, with partial independence from weight loss.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT